Title

Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease.

Document Type

Article

Publication Date

3-1-2018

Keywords

Biomarkers; Chemokines; Cytokines; Diabetic kidney disease; Inflammation

Abstract

Diabetic kidney disease (DKD) is the leading cause of CKD and end-stage kidney disease (ESKD) worldwide. Approximately 30-40% of people with diabetes develop this microvascular complication, placing them at high risk of losing kidney function as well as of cardiovascular events, infections, and death. Current therapies are ineffective for arresting kidney disease progression and mitigating risks of comorbidities and death among patients with DKD. As the global count of people with diabetes will soon exceed 400 million, the need for effective and safe treatment options for complications such as DKD becomes ever more urgent. Recently, the understanding of DKD pathogenesis has evolved to recognize inflammation as a major underlying mechanism of kidney damage. In turn, inflammatory mediators have emerged as potential biomarkers and therapeutic targets for DKD. Phase 2 clinical trials testing inhibitors of monocyte-chemotactic protein-1 chemokine C-C motif-ligand 2 and the Janus kinase/signal transducer and activator of transcription pathway, in particular, have produced promising results.

Clinical Institute

Kidney & Diabetes

Department

Endocrinology

Department

Nephrology

Volume

25

Issue

2

First Page

181

Last Page

191

PubMed ID

29580582

Journal Title

Advances in chronic kidney disease

Share

COinS